According to these findings, stratification of glioblastoma patients into three RPA classes was proposed: (i) RPA I class, MGMT levels ≤ median, age ≤ 50 years (median overall survival 21.9 months); (ii) RPA II class, MGMT levels ≥ median, age ≥ 50 years and c-Met level lower percentile (median overall survival 16.6 months); and (iii) RPA III class, MGMT protein levels ≥ median, age ≥ 50 years and c-Met levels higher percentile (median overall survival 9.4 moths) [50]. Here, MET is linked to glioblastoma.